Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006

D Turck, J Castenmiller, S De Henauw, K Hirsch‐Ernst, J Kearney, H Knutsen, A Maciuk, I Mangelsdorf, H McArdle, A Naska, C Pelaez, K. Pentieva, F Thies, S Tsabouri, M Vinceti, J‐L Bresson, A Siani

Research output: Contribution to journalArticle

Abstract

Following an application from H.J. Heinz Supply Chain Europe B.V. submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). The food Nutrimune (a pasteurised cow's skim milk fermented with Lactobacillus paracasei CBA L74) which is the subject of the health claim is sufficiently characterised. The Panel considers that immune defence against pathogens in GI tract and URT is a beneficial physiological effect. Two human intervention studies were submitted as being pertinent to the claim, which were evaluated by the Panel in the previous application. One human intervention study from which conclusions could be drawn showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the URT. The post hoc re‐analysis of the two human studies combined does not address the methodological limitations of the second study raised in the previous opinion, i.e. that the study was not planned, designed, randomised and analysed as a multicentre study, and that the large disparity of subjects in the three centres was not duly justified. The results from one animal study could support an effect of Nutrimune on defence against pathogens in the GI tract. No evidence was provided for a plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans. The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of Nutrimune and immune defence against pathogens in the GI tract and URT.
LanguageEnglish
Article numbere05656
Number of pages12
JournalEFSA Journal
Volume17
Issue number4
DOIs
Publication statusPublished - 15 Apr 2019

Fingerprint

health claims
Upper Gastrointestinal Tract
respiratory system
Respiratory System
gastrointestinal system
pathogens
Health
Food
Lactobacillus paracasei
novel foods
Netherlands
Allergens
Multicenter Studies
Gastrointestinal Tract
skim milk
supply chain
Milk
allergens
nutrition
cows

Keywords

  • Nutrimune
  • defence against pathogens
  • gastrointestinal tract
  • health claim
  • infection
  • children
  • upper respiratory tract

Cite this

Turck, D ; Castenmiller, J ; De Henauw, S ; Hirsch‐Ernst, K ; Kearney, J ; Knutsen, H ; Maciuk, A ; Mangelsdorf, I ; McArdle, H ; Naska, A ; Pelaez, C ; Pentieva, K. ; Thies, F ; Tsabouri, S ; Vinceti, M ; Bresson, J‐L ; Siani, A. / Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006. In: EFSA Journal. 2019 ; Vol. 17, No. 4.
@article{befd49a862e2485299cd2c4c13f13c0a,
title = "Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006",
abstract = "Following an application from H.J. Heinz Supply Chain Europe B.V. submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). The food Nutrimune (a pasteurised cow's skim milk fermented with Lactobacillus paracasei CBA L74) which is the subject of the health claim is sufficiently characterised. The Panel considers that immune defence against pathogens in GI tract and URT is a beneficial physiological effect. Two human intervention studies were submitted as being pertinent to the claim, which were evaluated by the Panel in the previous application. One human intervention study from which conclusions could be drawn showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the URT. The post hoc re‐analysis of the two human studies combined does not address the methodological limitations of the second study raised in the previous opinion, i.e. that the study was not planned, designed, randomised and analysed as a multicentre study, and that the large disparity of subjects in the three centres was not duly justified. The results from one animal study could support an effect of Nutrimune on defence against pathogens in the GI tract. No evidence was provided for a plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans. The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of Nutrimune and immune defence against pathogens in the GI tract and URT.",
keywords = "Nutrimune, defence against pathogens, gastrointestinal tract, health claim, infection, children, upper respiratory tract",
author = "D Turck and J Castenmiller and {De Henauw}, S and K Hirsch‐Ernst and J Kearney and H Knutsen and A Maciuk and I Mangelsdorf and H McArdle and A Naska and C Pelaez and K. Pentieva and F Thies and S Tsabouri and M Vinceti and J‐L Bresson and A Siani",
year = "2019",
month = "4",
day = "15",
doi = "10.2903/j.efsa.2019.5656",
language = "English",
volume = "17",
journal = "EFSA Journal",
issn = "1831-4732",
number = "4",

}

Turck, D, Castenmiller, J, De Henauw, S, Hirsch‐Ernst, K, Kearney, J, Knutsen, H, Maciuk, A, Mangelsdorf, I, McArdle, H, Naska, A, Pelaez, C, Pentieva, K, Thies, F, Tsabouri, S, Vinceti, M, Bresson, JL & Siani, A 2019, 'Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006', EFSA Journal, vol. 17, no. 4, e05656. https://doi.org/10.2903/j.efsa.2019.5656

Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006. / Turck, D; Castenmiller, J; De Henauw, S; Hirsch‐Ernst, K; Kearney, J; Knutsen, H; Maciuk, A; Mangelsdorf, I; McArdle, H; Naska, A; Pelaez, C; Pentieva, K.; Thies, F; Tsabouri, S; Vinceti, M; Bresson, J‐L; Siani, A.

In: EFSA Journal, Vol. 17, No. 4, e05656, 15.04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006

AU - Turck, D

AU - Castenmiller, J

AU - De Henauw, S

AU - Hirsch‐Ernst, K

AU - Kearney, J

AU - Knutsen, H

AU - Maciuk, A

AU - Mangelsdorf, I

AU - McArdle, H

AU - Naska, A

AU - Pelaez, C

AU - Pentieva, K.

AU - Thies, F

AU - Tsabouri, S

AU - Vinceti, M

AU - Bresson, J‐L

AU - Siani, A

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Following an application from H.J. Heinz Supply Chain Europe B.V. submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). The food Nutrimune (a pasteurised cow's skim milk fermented with Lactobacillus paracasei CBA L74) which is the subject of the health claim is sufficiently characterised. The Panel considers that immune defence against pathogens in GI tract and URT is a beneficial physiological effect. Two human intervention studies were submitted as being pertinent to the claim, which were evaluated by the Panel in the previous application. One human intervention study from which conclusions could be drawn showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the URT. The post hoc re‐analysis of the two human studies combined does not address the methodological limitations of the second study raised in the previous opinion, i.e. that the study was not planned, designed, randomised and analysed as a multicentre study, and that the large disparity of subjects in the three centres was not duly justified. The results from one animal study could support an effect of Nutrimune on defence against pathogens in the GI tract. No evidence was provided for a plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans. The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of Nutrimune and immune defence against pathogens in the GI tract and URT.

AB - Following an application from H.J. Heinz Supply Chain Europe B.V. submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). The food Nutrimune (a pasteurised cow's skim milk fermented with Lactobacillus paracasei CBA L74) which is the subject of the health claim is sufficiently characterised. The Panel considers that immune defence against pathogens in GI tract and URT is a beneficial physiological effect. Two human intervention studies were submitted as being pertinent to the claim, which were evaluated by the Panel in the previous application. One human intervention study from which conclusions could be drawn showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the URT. The post hoc re‐analysis of the two human studies combined does not address the methodological limitations of the second study raised in the previous opinion, i.e. that the study was not planned, designed, randomised and analysed as a multicentre study, and that the large disparity of subjects in the three centres was not duly justified. The results from one animal study could support an effect of Nutrimune on defence against pathogens in the GI tract. No evidence was provided for a plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans. The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of Nutrimune and immune defence against pathogens in the GI tract and URT.

KW - Nutrimune

KW - defence against pathogens

KW - gastrointestinal tract

KW - health claim

KW - infection

KW - children

KW - upper respiratory tract

UR - http://www.scopus.com/inward/record.url?scp=85065024956&partnerID=8YFLogxK

U2 - 10.2903/j.efsa.2019.5656

DO - 10.2903/j.efsa.2019.5656

M3 - Article

VL - 17

JO - EFSA Journal

T2 - EFSA Journal

JF - EFSA Journal

SN - 1831-4732

IS - 4

M1 - e05656

ER -